ClinicalTrials.gg
CompletedNCT03657290Updated Mar 22, 2019

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

A Phase 1 interventional study of vadadustat in Healthy, sponsored by Akebia Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-22.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a healthy volunteers study to assess the bioequivalence of vadadustat 450 mg tablets (Test A) compared to three 150mg tablets (Reference B). The study will also assess the effect of food on the bioavailability of vadadustat 450 mg tablet.

Read the detailed description

This is a randomized, open-label, single-dose, three-period crossover study in healthy adults to assess the bioequivalence of 3 X 150 mg vadadustat tablets (Test) compared to a single 450 mg vadadustat tablet (reference). Blood samples for vadadustat PK will be collected at pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, 32, 40, and 48 hours post-dose. The study will also assess the effect of food on vadadustat bioavailability by evaluating the pharmacokinetics of the 450 mg tablet in fed and fasted subjects.

02

Conditions studied

  • Healthy

Keywords

  • Vadadustat
  • healthy volunteers
  • bioequivalence
  • pharmacokinetics
03

In context

Lead sponsor

Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between ≥18 years and ≤55 years of age
  • Healthy subjects per Investigator judgment as documented by the medical history, physical examination, vital sign assessments, 12-lead (ECG), clinical laboratory assessments, and general observations.
  • Have a body weight ≥50 kg and (BMI) ≥18.5 kg/m2 to 29.5 kg/m2 inclusive
  • Understands the procedures, provides ICF and willing to comply with study requirements
  • Willing and able to comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease.
  • History of cancer (except non- melanoma skin cancer) or history of chemotherapy use.
  • Any surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to gastric bypass surgery or gastric or duodenal ulcers.
  • History of severe allergic or anaphylactic reactions. Chronic daily medication use.
  • History of drug abuse Excessive alcohol consumption.
  • Smoking and the use of nicotine-containing products
  • Consumption of grapefruit or grapefruit juice, pomelo, star fruit, Seville or Moro (blood) orange, or their associated products
  • Participation in another clinical trial or exposure to any agent.
  • Donation of blood or significant blood loss or plasma donation.
  • Any condition that would interfere with the ability to provide , comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Active comparator
    Treatment A

    vadadustat 3 X 150 mg Tablets in fasted subjects

    Drug: vadadustat

  • Active comparator
    Treatment B

    Vadadustat 1 X 450 mg Tablets in fasted subjects

    Drug: vadadustat

  • Active comparator
    Treatment C

    vadadustat 1 X 450 mg Tablets in fed subjects

    Drug: vadadustat

Interventions

  • Vadadustat Tablets

    Also known as: AKB-6548

06

What researchers measure

Primary outcomes

  1. Bioequivalence - Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)

    Time frame: Baseline visit, 48 hours

  2. Bioequivalence - Area under plasma concentration-time curve from 0 to infinity (AUCinf)

    Time frame: Baseline visit, 48 hours

  3. Bioequivalence - Area under plasma concentration-time curve from 0 to last sampling point (AUCall)

    Time frame: Baseline visit, 48 hours

  4. Bioequivalence - Observed Maximum concentration (Cmax)

    Time frame: Baseline visit, 48 hours

  5. Measure Food Effect - Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)

    Time frame: Baseline visit, 48 hours

  6. Measure Food Effect - 2. Area under plasma concentration-time curve from 0 to infinity (AUCinf)

    Time frame: Baseline visit, 48 hours

  7. Measure Food Effect - 2.3. Observed Maximum concentration (Cmax)

    Time frame: Baseline visit, 48 hours

Secondary outcomes

  1. Time to reach Cmax

    Time frame: Baseline visit, 48 hours

  2. Time to reach Tmax

    Time frame: Baseline visit, 48 hours

  3. Mean residence time (MRT)

    Time frame: Baseline visit, 48 hours

  4. Elimination rate constant (Kel)

    Time frame: Baseline visit, 48 hours

  5. Apparent total body clearance (CL/F)

    Time frame: Baseline visit, 48 hours

  6. Apparent volume of distribution (Vd/F)

    Time frame: Baseline visit, 48 hours

  7. Terminal half-life (t1/2)

    Time frame: Baseline visit, 48 hours

  8. Percentage of extrapolated area under the curve from time t to infinity (AUCextrap or Residual Area)

    Time frame: Baseline visit, 48 hours

07

Study locations

1 site
  • Paraxel International
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2018
First posted
Sep 5, 2018
StartActual
Aug 3, 2018
Primary completionActual
Oct 16, 2018
CompletionActual
Oct 16, 2018
Last update
Mar 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03657290
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Aug 3, 2018
Primary completion
Oct 16, 2018
Completion
Oct 16, 2018
Last update
Mar 22, 2019

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion